Publications by authors named "Birgit Bossenmaier"

Claim this Profile
T
The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.
Janet K Peper-Gabriel, Marina Pavlidou, Lucia Pattarini, Aizea Morales-Kastresana, Thomas J Jaquin, Birgit Bossenmaier

Clin Cancer Res· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
Denis M Collins, Stephen F Madden, Nicola Gaynor, Dalal AlSultan, Marion Le Gal, Birgit Bossenmaier

Clin Cancer Res· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity.
Claudio Sustmann, Steffen Dickopf, Jörg T Regula, Hubert Kettenberger, Michael Mølhøj, Birgit Bossenmaier

MAbs· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translation and evaluation of a pre-clinical 5-protein response prediction signature in a breast cancer phase Ib clinical trial.
Axel Ducret, Ian James, Sabine Wilson, Martina Feilke, Andreas Tebbe, Birgit Bossenmaier

PLoS One· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acquired Resistance to Antibody-Drug Conjugates.
Denis M Collins, Birgit Bossenmaier, Gwendlyn Kollmorgen, Gerhard Niederfellner

Cancers (Basel)· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.
Denis Collins, Wolfgang Jacob, Juan Miguel Cejalvo, Maurizio Ceppi, Ian James, Birgit Bossenmaier

PLoS One· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.
Didier Meulendijks, Wolfgang Jacob, Emile E Voest, Morten Mau-Sorensen, Maria Martinez-Garcia, Birgit Bossenmaier

Clin Cancer Res· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity.
Yasmin Leshem, James O'Brien, Xiufen Liu, Tapan K Bera, Masaki Terabe, Birgit Bossenmaier

Cancer Immunol Res· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.
Frieder Bauss, Martin Lechmann, Ben-Fillippo Krippendorff, Roland Staack, Frank Herting, Birgit Bossenmaier

Mol Oncol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.
Didier Meulendijks, Wolfgang Jacob, Maria Martinez-Garcia, Alvaro Taus, Martijn P Lolkema, Birgit Bossenmaier

Clin Cancer Res· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deciphering the stepwise binding mode of HRG1β to HER3 by surface plasmon resonance and interaction map.
Carmen Peess, Leopold von Proff, Sabine Goller, Karl Andersson, Michael Gerg, Birgit Bossenmaier

PLoS One· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody.
Georgina Meneses-Lorente, Thomas Friess, Irene Kolm, Gabriele Hölzlwimmer, Sabine Bader, Birgit Bossenmaier

Cancer Chemother Pharmacol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116.
Anton G T Terwisscha van Scheltinga, Marjolijn N Lub-de Hooge, Keelara Abiraj, Carolien P Schröder, Linda Pot, Birgit Bossenmaier

MAbs· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of bispecific molecules for the in situ detection of protein-protein interactions and protein phosphorylation.
Jan van Dieck, Volker Schmid, Dieter Heindl, Sebastian Dziadek, Michael Schraeml, Birgit Bossenmaier

Chem Biol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody mediated CDCP1 degradation as mode of action for cancer targeted therapy.
Gwendlyn Kollmorgen, Gerhard Niederfellner, Alexander Lifke, Gloria J Spohn, Natascha Rieder, Birgit Bossenmaier

Mol Oncol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation.
Christian Mirschberger, Christian B Schiller, Michael Schräml, Nikolaos Dimoudis, Thomas Friess, Birgit Bossenmaier

Cancer Res· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural requirements for cub domain containing protein 1 (CDCP1) and Src dependent cell transformation.
Gwendlyn Kollmorgen, Birgit Bossenmaier, Gerhard Niederfellner, Hans-Ulrich Häring, Reiner Lammers

PLoS One· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.
Christian A Gerdes, Valeria Gonzalez Nicolini, Sylvia Herter, Erwin van Puijenbroek, Sabine Lang, Birgit Bossenmaier

Clin Cancer Res· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing.
Silke Metz, Christian Panke, Alexander K Haas, Jürgen Schanzer, Wilma Lau, Birgit Bossenmaier

Protein Eng Des Sel· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
Werner Scheuer, Thomas Friess, Helmut Burtscher, Birgit Bossenmaier, Josef Endl

Cancer Res· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The 1.1 A resolution crystal structure of the p130cas SH3 domain and ramifications for ligand selectivity.
Magdalena Wisniewska, Birgit Bossenmaier, Guy Georges, Friederike Hesse, Markus Dangl

J Mol Biol· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis